Clinical Trial Update: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing chidamide plus anti-PD-1 antibody and peg-aspargase versus DDGP in newly diagnosed stage III-IV extranodal natural killer/T-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Chidamide (chidamide)
• DDGP
• Pegaspargase (pegaspargase)

Snippet

Sponsor: Ruijin Hospital | Conditions: Extranodal Natural Killer T Cell Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING